Skip to main content
Erschienen in: World Journal of Urology 1/2017

17.05.2016 | Original Article

Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer

verfasst von: Neil J. Kocher, Chris Rjepaj, Haley Robyak, Erik Lehman, Jay D. Raman

Erschienen in: World Journal of Urology | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To determine whether individual and/or cumulative components of metabolic syndrome (obesity, hypertension, dyslipidemia, and hyperglycemia) are associated with pathologic features of kidney cancer.

Patients and methods

A review of our kidney tumor database identified 462 patients who underwent partial or radical nephrectomy for renal cell carcinoma. The NCEP ATP-III criteria were used to define metabolic syndrome (MetS). Linear fixed effects modeling and ordinal logistic regression examined the relationship between MetS (individual and cumulative components) and pathologic characteristics.

Results

Two hundred and seventy-eight men and 184 women with a median age of 58 years, BMI of 31 kg/m2, tumor size of 3.7 cm, and nephrometry score of 6 were included. Ninety-seven (21 %) patients met NCEP ATP-III criteria for MetS. Hypertension was the only individual component of MetS associated with pathologic features of kidney cancer including increased tumor size [geometric mean ratio 1.17 (1.05–1.32), P = 0.03], higher tumor grade [OR 1.49 (1.03–2.17), P = 0.04], increasing nephrometry score [OR 1.77 (1.28–2.48), P = 0.001], and non-clear cell histology [OR 1.42 (1.01–2.02), P = 0.05]. Furthermore, combinations of MetS components were associated with increased tumor grade (P = 0.02), tumor stage (P = 0.02), nephrometry score (P ≤ 0.001), and non-clear cell histology (P = 0.02), only when hypertension was included.

Conclusion

MetS is composed of four risk factors each implicated in carcinogenesis. We identified hypertension as the primary component associated with specific pathologic features of kidney cancer. Further studies are necessary to elucidate whether the effect of hypertension is a function of severity and/or chronicity.
Literatur
2.
Zurück zum Zitat Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH (2002) Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev 11:171–178CrossRefPubMed Mathew A, Devesa SS, Fraumeni JF Jr, Chow WH (2002) Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev 11:171–178CrossRefPubMed
3.
Zurück zum Zitat Weikert S, Ljungberg B (2010) Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 28:247–252CrossRefPubMed Weikert S, Ljungberg B (2010) Contemporary epidemiology of renal cell carcinoma: perspectives of primary prevention. World J Urol 28:247–252CrossRefPubMed
4.
5.
Zurück zum Zitat Benichou J, Chow WH, McLaughlin JK, Mandel JS, Fraumeni JF Jr (1998) Population attributable risk of renal cell carcinoma in Minnesota. Am J Epidemiol 148:424–430CrossRefPubMed Benichou J, Chow WH, McLaughlin JK, Mandel JS, Fraumeni JF Jr (1998) Population attributable risk of renal cell carcinoma in Minnesota. Am J Epidemiol 148:424–430CrossRefPubMed
6.
Zurück zum Zitat Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRefPubMed Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371:569–578CrossRefPubMed
7.
Zurück zum Zitat Chow WH, Gridley G, Fraumani JF Jr, Jarvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343:1305–1311CrossRefPubMed Chow WH, Gridley G, Fraumani JF Jr, Jarvholm B (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343:1305–1311CrossRefPubMed
8.
Zurück zum Zitat Flaherty KT, Fuchs CS, Colditz GA et al (2005) A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Cause Control 16:1099–1106CrossRef Flaherty KT, Fuchs CS, Colditz GA et al (2005) A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Cause Control 16:1099–1106CrossRef
9.
Zurück zum Zitat Weikert S, Boeing H, Pischon T et al (2008) Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 167:438–446CrossRefPubMed Weikert S, Boeing H, Pischon T et al (2008) Blood pressure and risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Am J Epidemiol 167:438–446CrossRefPubMed
12.
Zurück zum Zitat Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRef
13.
Zurück zum Zitat Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (2013) Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010. J Am Coll Cardiol 62:697–703CrossRefPubMedPubMedCentral Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (2013) Prevalence and trends of metabolic syndrome in the adult US population, 1999–2010. J Am Coll Cardiol 62:697–703CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Survey. JAMA 287:356–359CrossRefPubMed Ford ES, Giles WH, Dietz WH (2002) Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Survey. JAMA 287:356–359CrossRefPubMed
15.
Zurück zum Zitat Bulut S, Aktas BK, Erkmen AE et al (2014) Metabolic syndrome prevalence in renal cell cancer patients. Asian Pac J Cancer Prev 15:7925–7928CrossRefPubMed Bulut S, Aktas BK, Erkmen AE et al (2014) Metabolic syndrome prevalence in renal cell cancer patients. Asian Pac J Cancer Prev 15:7925–7928CrossRefPubMed
16.
Zurück zum Zitat Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC (2002) Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 13:287–293CrossRefPubMed Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC (2002) Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer Causes Control 13:287–293CrossRefPubMed
17.
Zurück zum Zitat Colt JS, Schwartz K, Graubard BI et al (2011) Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 22:797–804PubMedPubMedCentral Colt JS, Schwartz K, Graubard BI et al (2011) Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology 22:797–804PubMedPubMedCentral
18.
Zurück zum Zitat Corrao G, Scotti L, Bagnardi V, Sega R (2007) Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2:125–133CrossRefPubMed Corrao G, Scotti L, Bagnardi V, Sega R (2007) Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf 2:125–133CrossRefPubMed
19.
Zurück zum Zitat Shapiro JA, Williams MA, Weiss NS et al (1999) Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 149:521–530CrossRefPubMed Shapiro JA, Williams MA, Weiss NS et al (1999) Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 149:521–530CrossRefPubMed
20.
Zurück zum Zitat Fryzek JP, Poulsen AH, Johnsen SP et al (2005) A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer 92:1302–1306CrossRefPubMedPubMedCentral Fryzek JP, Poulsen AH, Johnsen SP et al (2005) A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer 92:1302–1306CrossRefPubMedPubMedCentral
Metadaten
Titel
Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer
verfasst von
Neil J. Kocher
Chris Rjepaj
Haley Robyak
Erik Lehman
Jay D. Raman
Publikationsdatum
17.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 1/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-016-1850-2

Weitere Artikel der Ausgabe 1/2017

World Journal of Urology 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.